## Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For commercial members only, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at

1-800-437-3803 for a	ssistance.	
	PATIENT INFORMATION	PHYSICIAN INFORMATION
Name N		ame
ID Number		pecialty
		ddress
□ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □ □		ity /State/Zip
Drug Name OXLUMO Pho		hone:
Fa Dose and Quantity NI		
		Contact Person
		Contact Person Phone
/ Ext.		Ext.
	EASE STATE INFORMATION ired Demographic Information:	
Patient Weight:kg		
	Patient Height:ftinches	
Will the provider be administering the medication to the FEP member within the health plan's geographic service area?  ☐ Yes ☐ No If No, a prior authorization is not required through this process.		
you a		iced by a provider within the health plan's geographic service area. If the health plan for questions regarding the FEP member's benefit
[ [	benefit and additional information.	ess. Please contact the member's primary coverage for determination of
	ria Questions: atient's diagnosis?	
□Primary hyperoxaluria type 1 (PH1)		
Other diagnosis (please specify):		
2. Has the patient received a liver transplant? □Yes □No		
3. Will the patient be dosed based on actual body weight? □Yes □No		
4. Has the patient been on this medication continuously for the last 6 months excluding samples? Please select answer below		
□ NO – this is INITIATION of therapy, please answer the following question:		
a. Has the patient's diagnosis been confirmed by identification of biallelic pathogenic variants in alanine: glyoxylate aminotransferase (AGT or AGXT) gene OR liver biopsy demonstrating AGT deficiency?		
b. Does the patient have an elevated urine oxalate excretion level equal to or greater than 0.7 millimoles per 1.73 square meter? \(\square\) Yes		
c. Does the patient have an elevated plasma oxalate concentration level greater than 20 micromoles per liter or greater than 1.76 milligrams per liter?		
□Yes □No		
d. Does the patient have a urine oxalate excretion to creatinine ratio above age-specific upper limit of normal? □Yes □No		
e. Does the patient have an estimated glomerular filtration rate (eGFR) greater than 30 milliliters per minute per 1.73 square meter?   No		
f. Does the prescriber agree to monitor urinary oxalate levels?   Yes   No		
g. Is this medication being prescribed by or in consultation with a nephrologist, urologist, geneticist, or any healthcare provider with expertise in treating primary hyperoxaluria type 1? □Yes □No		
	is is a PA renewal for <b>CONTINUATION</b> of therapy, please answe	r the following questions:
	e patient had a clinically meaningful response to therapy from pre-	
Chart notes are required for the processing of all requests. Please add any other supporting medical information necessary for our review (required)		
	Coverage will not be provided if the prescribing physician	s signature and date are not reflected on this document.
☐ Request for expedited review: I certify that applying the standard review time frame may seriously jeopardize the life or health of the member or the member's ability to regain maximum function		
Physician's Name Step 2:	Physician Signature  Form Completely Filled Out	Date
Checklist	☐ Provide chart notes	☐ Attach test results
Step 3: Submit	By Fax: BCBSM Specialty Pharmacy Mailbox 1-877-325-5979	By Mail: BCBSM Specialty Pharmacy Program P.O. Box 312320, Detroit, MI 48231-2320